Adoption of high-sensitivity troponin assays that meet International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) guidelines is recommended by the recently released “Fourth Universal Definition of Myocardial Infarction.” By their high precision and analytic sensitivity, these assays offer new insights into troponin levels in women and other populations, including those with coronary artery disease. The assays also support shorter interval serial measurement strategies for managing patients with possible acute myocardial infarction in the emergency department (ED).
Many stakeholders in the healthcare system are impacted by these insights, including laboratorians, nurses, cardiologists and emergency medicine physicians. Understanding and addressing unique concerns of all stakeholder groups is key to the implementation of these new assays.
In this webinar, Dr. Jeannine Holden will discuss the concerns surrounding adoption of high-sensitivity troponin testing for patients with coronary artery disease and acute myocardial infarction.
After attending the webinar, you will be able to:
- Understand the IFCC’s precision requirements for high-sensitivity troponin assays
- Identify when to implement the recommended guidelines for use of high-sensitivity troponin testing
- Develop strategies for identifying and engaging cardiology and emergency medicine stakeholders
- Assess the impact of education on the adoption of high-sensitivity troponin assays
Presenter: Jeannine T. Holden, M.D., MBA
Dr. Jeannine Holden is vice president of medical and scientific affairs and chief medical officer at Beckman Coulter Diagnostics. Prior to joining Beckman Coulter in 2013, she was an associate professor and director of hematopathology and flow cytometry at Emory University School of Medicine.